This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of PLX4032 in Patients With Solid Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2015 by Plexxikon.
Recruitment status was:  Active, not recruiting
Roche Pharma AG
Information provided by (Responsible Party):
Plexxikon Identifier:
First received: November 28, 2006
Last updated: June 19, 2015
Last verified: June 2015
The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic mutation.

Condition Intervention Phase
Malignant Melanoma Colorectal Carcinoma Drug: PLX4032 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors

Resource links provided by NLM:

Further study details as provided by Plexxikon:

Primary Outcome Measures:
  • Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, ECGs and clinical laboratory tests [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Pharmacodynamic activity in tumor biopsy tissue as assess by paired biopsy (Day 15 vs. Baseline) quantitation of pERK and Ki67 [ Time Frame: 3-6 months ]

Estimated Enrollment: 75
Study Start Date: November 2006
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PLX4032
Open-label, sequential dose escalation
Drug: PLX4032
Oral capsules administered BID

Detailed Description:

Activating mutations of the BRAF gene have been observed in a variety of cancers, including 55-68% of malignant melanomas. In general, oncogenic mutations of BRAF correlate with a poor outcome. PLX4032 is a compound that selectively inhibits oncogenic B-Raf kinase.

Two extension cohorts of patients with confirmed V600E mutations will be recruited, consisting of advanced melanoma and metastatic colorectal carcinoma.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Solid tumors confirmed histologically whose tumors are refractory to standard therapy, or for whom standard or curative therapy does not exist
  • Patients from whom paired melanoma biopsies are planned must have a V600E+ BRAF mutation confirmed prior to the administration of PLX4032
  • Previous chemotherapy, immunotherapy, or radiation therapy must have been completed at least 2 weeks prior to starting PLX4032 therapy, and all associated toxicity must be resolved prior to administration of PLX4032
  • Patients in the Extension cohorts (melanoma or adenocarcinoma of the colon or rectum) must have both a V600E+ BRAF mutation and measurable disease (by RECIST V 1.0 criteria) prior to the administration of PLX4032. All patients enrolled must provide archival or fresh melanoma tumor biopsy for confirmation of V600E+ BRAF mutation status by TaqMan assay
  • ECOG performance status 0 or 1
  • Life expectancy ≥ 3 months
  • Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

  • Brain metastases that are progressing or have been documented to be stable for less than 3 months, or for which systemic corticosteroids are required
  • Investigational drug use within 28 days of the first dose of PLX4032
  • Uncontrolled intercurrent illness
  • Refractory nausea and vomiting, malabsorption, or significant bowel resection that would preclude adequate absorption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00405587

United States, California
University of California Los Angeles
Los Angeles, California, United States, 90095
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Australia, Victoria
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia, 3002
Royal Melbourne Hospital
Parkville, Victoria, Australia
Sponsors and Collaborators
Roche Pharma AG
Study Director: Henry Hsu, MD Plexxikon
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Plexxikon Identifier: NCT00405587     History of Changes
Other Study ID Numbers: PLX06-02
Study First Received: November 28, 2006
Last Updated: June 19, 2015

Additional relevant MeSH terms:
Colorectal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on August 17, 2017